Gilead to acquire Arcellx for $115 per share in cash plus CVR, implied $7.8 billion
Gilead Sciences agreed on February 22, 2026 to acquire Arcellx through a tender offer followed by a second-step merger, offering $115 per share in cash plus one contingent value right worth up to $5 per share if anito-cel cumulative sales reach $6.0 billion by year-end 2029. The company said the deal implies an equity value of $7.8 billion and is expected to close in the second quarter of 2026, which would add a large, pre-approval acquisition to Gilead's balance sheet and affect shareholders through its cost and future earnings contribution.
Key points
- Offer price of $115 per share in cash plus one CVR paying $5 per share on cumulative anito-cel sales of at least $6.0 billion through 2029
- Implied equity value of $7.8 billion; Gilead already owns about 11.5 percent of Arcellx's common stock
- Expected close in the second quarter of 2026, subject to tender, regulatory and other conditions
- Arcellx would pay Gilead a $260 million termination fee in specified circumstances; the deal is expected to be accretive to earnings per share in 2028 and thereafter, after FDA approval of anito-cel
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.